CTRO-1035

CTRO-1035 is a preclinical-stage liver-targeted oligonucleotide developed by insitro for the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD), specifically addressing liver fat accumulation and fibrosis. The drug was discovered using insitro's proprietary machine learning platform, which identifies genetic drivers of disease. CTRO-1035 is designed to modulate the expression of Insulin Receptor Substrate 1 (IRS1), a protein involved in insulin signaling that plays a critical role in hepatic metabolism. The development of this asset is supported by a partnership with Eli Lilly, which provides modality-specific expertise, while insitro retains full global commercial rights.